A total of 22 studies (n=3,121, range 12 to 792) were included in the review.
In trials that prescribed pegylated interferon plus ribavirin, the median rate of SVR among injecting drug users was 54.3% (range 18.1% to 94.1%; nine studies). When all chronic hepatitis C trials that included injecting drug users were combined, regardless of treatment regimen, the median rate of SVR among injecting drug users was 40.6% (range 15.8% to 94.1%). No studies that included non-injecting drug user comparison groups reported a statistically significant difference between rate of SVR among injecting drug users and non-injecting drug users.
Among individuals in whom treatment was initiated for acute hepatitis C, SVR was 68.5% for 89 injecting drug users versus 81.5% for 65 non-injecting drug users (seven studies). For groups of injecting drug users who were enrolled in drug treatment programs prior to the initiation of hepatitis C treatment, median SVR rate was 47.6% (range 27.6% to 94.1%%; 13 studies)